Treatment of immunodeficiency with interleukin-2: Initial exploration

Roland Mertelsmann; Karl Welte; Cora Sternberg; Richard O’Reilly; Malcolm A.S. Moore; Bayard D. Clarkson; Herbert F. Oettgen

Treatment of immunodeficiency with interleukin-2: Initial exploration

Roland Mertelsmann, Karl Welte, Cora Sternberg, Richard O’Reilly, Malcolm A.S. Moore, Bayard D. Clarkson, Herbert F. Oettgen

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Fifteen patients with acquired immunodeficiency syndrome (AIDS), lymphoma and immunodeficiency, or severe combined immunodeficiency were treated with highly purified interleukin-2 (IL-2) prepared from human lymphocytes. All patients showed a defect in mitogen-induced T cell proliferation which was partially corrected when IL-2 was added in vitro. IL-2 was administered subcutaneously by daily injection or continuous infusion. The maximum daily dose was 20,000 U/m², the maximum total dose 855,000 U/m², and the maximum period of treatment 77 days. An increase in the platelet count was seen in one patient with AIDS, a decrease in the serum level of a monoclonal immunoglobulin in another patient with AIDS, and a minor tumor response in a patient with diffuse histiocytic lymphoma. As no toxicity was observed, further study of IL-2 in the treatment of human immunodeficiency is indicated.

Original language	English
Pages (from-to)	483-490
Number of pages	8
Journal	Journal of Biological Response Modifiers
Volume	3
Issue number	5
State	Published - Oct 1984
Externally published	Yes

Keywords

Immunodeficiency
Interleukin-2
Mitogens
Toxicity
Tumor response

Cite this

@article{79bb19a5e97b433dac4adcb345369fab,

title = "Treatment of immunodeficiency with interleukin-2: Initial exploration",

abstract = "Fifteen patients with acquired immunodeficiency syndrome (AIDS), lymphoma and immunodeficiency, or severe combined immunodeficiency were treated with highly purified interleukin-2 (IL-2) prepared from human lymphocytes. All patients showed a defect in mitogen-induced T cell proliferation which was partially corrected when IL-2 was added in vitro. IL-2 was administered subcutaneously by daily injection or continuous infusion. The maximum daily dose was 20,000 U/m2, the maximum total dose 855,000 U/m2, and the maximum period of treatment 77 days. An increase in the platelet count was seen in one patient with AIDS, a decrease in the serum level of a monoclonal immunoglobulin in another patient with AIDS, and a minor tumor response in a patient with diffuse histiocytic lymphoma. As no toxicity was observed, further study of IL-2 in the treatment of human immunodeficiency is indicated.",

keywords = "Immunodeficiency, Interleukin-2, Mitogens, Toxicity, Tumor response",

author = "Roland Mertelsmann and Karl Welte and Cora Sternberg and Richard O{\textquoteright}Reilly and Moore, {Malcolm A.S.} and Clarkson, {Bayard D.} and Oettgen, {Herbert F.}",

year = "1984",

month = oct,

language = "English",

volume = "3",

pages = "483--490",

journal = "Journal of Biological Response Modifiers",

issn = "0732-6580",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Treatment of immunodeficiency with interleukin-2

T2 - Initial exploration

AU - Mertelsmann, Roland

AU - Welte, Karl

AU - Sternberg, Cora

AU - O’Reilly, Richard

AU - Moore, Malcolm A.S.

AU - Clarkson, Bayard D.

AU - Oettgen, Herbert F.

PY - 1984/10

Y1 - 1984/10

N2 - Fifteen patients with acquired immunodeficiency syndrome (AIDS), lymphoma and immunodeficiency, or severe combined immunodeficiency were treated with highly purified interleukin-2 (IL-2) prepared from human lymphocytes. All patients showed a defect in mitogen-induced T cell proliferation which was partially corrected when IL-2 was added in vitro. IL-2 was administered subcutaneously by daily injection or continuous infusion. The maximum daily dose was 20,000 U/m2, the maximum total dose 855,000 U/m2, and the maximum period of treatment 77 days. An increase in the platelet count was seen in one patient with AIDS, a decrease in the serum level of a monoclonal immunoglobulin in another patient with AIDS, and a minor tumor response in a patient with diffuse histiocytic lymphoma. As no toxicity was observed, further study of IL-2 in the treatment of human immunodeficiency is indicated.

AB - Fifteen patients with acquired immunodeficiency syndrome (AIDS), lymphoma and immunodeficiency, or severe combined immunodeficiency were treated with highly purified interleukin-2 (IL-2) prepared from human lymphocytes. All patients showed a defect in mitogen-induced T cell proliferation which was partially corrected when IL-2 was added in vitro. IL-2 was administered subcutaneously by daily injection or continuous infusion. The maximum daily dose was 20,000 U/m2, the maximum total dose 855,000 U/m2, and the maximum period of treatment 77 days. An increase in the platelet count was seen in one patient with AIDS, a decrease in the serum level of a monoclonal immunoglobulin in another patient with AIDS, and a minor tumor response in a patient with diffuse histiocytic lymphoma. As no toxicity was observed, further study of IL-2 in the treatment of human immunodeficiency is indicated.

KW - Immunodeficiency

KW - Interleukin-2

KW - Mitogens

KW - Toxicity

KW - Tumor response

UR - http://www.scopus.com/inward/record.url?scp=0021134368&partnerID=8YFLogxK

M3 - Article

C2 - 6334136

AN - SCOPUS:0021134368

SN - 0732-6580

VL - 3

SP - 483

EP - 490

JO - Journal of Biological Response Modifiers

JF - Journal of Biological Response Modifiers

IS - 5

ER -

Treatment of immunodeficiency with interleukin-2: Initial exploration

Abstract

Keywords

Fingerprint

Cite this